Lupin Q2 profit falls while sales rise as EBITDA margins contract

Key Points

Lupin’s Q2 FY27 net profit falls about 22% year on year to ₹1,155.3 crore.
Revenue from operations rises to around ₹7,827 crore in Q2 FY27.
EBITDA declines year on year, with EBITDA margins contracting versus the prior year quarter.
Outlets cite US generic competition as a contributor to near-term margin pressure.
Free Press Journal mentions US FDA tentative approval for apixaban oral suspension 1.25mg/mL.

Where coverage differs

All three outlets agree on the core direction of results: net profit declines in Q2 FY27 while revenue from operations increases. However, the depth and focus differ. NDTV foregrounds brokerage commentary (Jefferies target cut) and attribution to US generic competition, while Free Press Journal and Business Line focus more on reported financial metrics. Free Press Journal also provides additional items absent from the other summaries, including a US FDA tentative approval for apixaban, quarter-on-quarter comparisons, and detailed segment/geography growth and margin changes. The specific EBITDA and margin figures also vary in emphasis across outlets, reflecting different editorial selections rather than outright contradictions in the summaries provided.

See what each outlet emphasised ↓

Lupin Q2 profit falls while sales rise as EBITDA margins contract

Photo: NDTV

Lupin reports weaker profitability in its latest quarter, with profit after tax declining year on year while sales increase. Multiple outlets say net profit falls 22.2% to ₹1,155.3 crore for Q2 FY27, and that EBITDA declines in double digits as margins contract.

At the same time, outlets highlight growth in revenue from operations and product sales. Free Press Journal and Business Line note revenue from operations rises to about ₹7,827 crore and product sales grow, with Free Press Journal adding a breakdown showing gains in India and the US. Free Press Journal also includes a mention that Lupin receives US FDA tentative approval for an apixaban oral suspension.

Brokerage expectations also shape coverage. NDTV focuses on broker actions and near-term headwinds, citing Jefferies cutting its target and flagging US generic competition as a factor behind margin pressure. Across the reports, the consistent theme is margin contraction alongside stronger top-line performance, though outlets vary in how much detail they provide on segment performance and brokerage commentary.

This summary is generated automatically from the reporting of the outlets listed on this page. Follow their links for the full coverage.

How Outlets Covered This Story

NDT

NDTV

Independent

Lupin Q2 Review: Jefferies Cuts Target 15%, Flags US Competition; Kotak Retains Add

NDTV leads with brokerage framing, stressing Jefferies’ target cut and US generic competition as the near-term driver of margin pressure, alongside EBITDA/margin changes.

3 hours ago

FRE

Free Press Journal

Independent

Lupin Q2 FY27 Results Reveal A Mixed Earnings Picture, Net Profit Declines 22% To ₹1,155 Crore Even As Sales Register A Healthy 14% Growth

Free Press Journal leads with a mixed-results headline—net profit down but sales up—then adds granular financial breakdowns by geography and mentions a US FDA tentative approval.

1 day ago

BUS

Business Line - Home

Centre-right

Lupin Q2 net profit falls 22.19% to ₹1,155.3 crore

Business Line emphasises the headline result—net profit falling 22.19%—and pairs it with the reported increase in revenue from operations, with fewer additional details.

1 day ago

We use cookies

This website uses cookies in order to enhance the overall user experience.

Take a look at our Cookies Policy for more information.

Lupin Q2 profit falls while sales rise as EBITDA margins contract

Where coverage differs

Hoban becomes Hanjin KAL’s largest shareholder, sparking control-battle speculation

Moniepoint users get USSD code to check eligibility for FG’s ₦50,000 grant

South Africa faces job risk as US plans AGOA trade benefit end in 2027